Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Privia Health Group, Inc. (Nasdaq: PRVA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Privia Health is a Delaware-incorporated, technology-driven physician enablement company based in Arlington, Virginia, and its filings offer detailed information about its financial condition, operations, governance, and material events.
Among the most frequently referenced documents are current reports on Form 8-K, which Privia Health uses to announce quarterly financial results, guidance updates, and other significant developments. For example, the company has filed 8-Ks to furnish press releases covering its first, second, and third quarter results, including metrics such as total revenue, net income, Adjusted EBITDA, Implemented Providers, Value-Based Care Attributed Lives, Practice Collections, Care Margin, and Platform Contribution. It has also filed 8-Ks to describe material events like the definitive agreement to acquire an Accountable Care Organization business from Evolent Health, Inc., and changes in its Board of Directors.
Investors analyzing PRVA can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR) to review segment information, risk factors, non-GAAP reconciliations, and detailed discussions of the company’s value-based care model and physician enablement platform. These filings also elaborate on regulatory risks, relationships with medical groups and providers, and dependencies on key technology vendors.
On Stock Titan, Privia Health filings are complemented by AI-powered summaries that explain the key points of lengthy documents such as 10-Ks and 10-Qs, and highlight notable items in 8-Ks. Users can quickly see what changed from prior periods, how management describes performance in value-based care programs like the Medicare Shared Savings Program, and where guidance or risk disclosures have been updated. The platform also surfaces relevant insider and governance-related filings, helping readers track board appointments, compensation plans, and other corporate actions disclosed to the SEC.
PRVA notice under Rule 144 reporting planned/resumed sales of Common Stock and recent dispositions by an affiliated holder. The filing lists a restricted stock vesting delivery of 6,391 shares on 03/13/2026 as compensation and multiple sales by David Mountcastle during Feb–Mar 2026 with dated share quantities and proceeds.
PRVA issuer notice: a Form 144 reports an intended sale of 27,229 shares of common stock tied to restricted stock vesting on 03/12/2026.
Parth Mehrotra reported multiple cash sales during March 2026: 21,440 shares on 03/06/2026, 41,999 on 03/09/2026, 21,097 on 03/10/2026, and 26,763 on 03/12/2026.
PRVA reported insider sales by David Mountcastle. The filing lists multiple dispositions of Common Stock under Rule 144 on 02/26/2026 (5,361 shares, $134,030.87), 02/27/2026 (7,697 shares, $192,798.08), 03/06/2026 (5,177 shares, $119,852.73), 03/09/2026 (5,829 shares, $133,158.26), and 03/12/2026 (6,453 shares, $141,317.47).
Privia Health Group Chief Executive Officer Parth Mehrotra reported a mix of stock awards and a planned share sale. He received 171,904 shares of common stock as a grant or award on March 11, 2026, and 141,342 shares as a grant or award on March 10, 2026, both at no cash cost to him.
On March 10, 2026, he sold 21,097 shares of common stock at a weighted average price of $22.71 per share, with individual trade prices ranging from $22.27 to $23.23, under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 635,944 shares of Privia Health Group common stock.
Fargis Edward C reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group, Inc. executive vice president and general counsel Edward C. Fargis reported receiving a grant of 28,268 shares of common stock in the form of restricted stock units at no cash cost per share. These units were awarded under the 2021 Omnibus Incentive Plan.
The restricted stock units will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally contingent on continued service through each vesting date. Following this grant, Fargis directly holds 111,979 shares of common stock.
Mountcastle David reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group EVP & CFO David Mountcastle reported equity awards of common stock. He received 42,584 shares and 35,335 shares of common stock at a price of $0.00 per share as compensation grants, increasing his direct holdings to 239,822 shares.
Footnotes explain these shares relate to restricted stock units under the 2021 Omnibus Incentive Plan that vest in three equal annual installments and to performance stock units granted on May 9, 2023 for the 2023–2025 performance period that have now vested and been distributed. An additional 8,695 shares are held indirectly by his spouse.
Parth Mehrotra reported sales of Common Stock under Rule 144. The filing lists sales of 21,440 shares on 03/06/2026, 41,999 shares on 03/09/2026 and 21,097 shares on 03/10/2026. The excerpt also shows a Restricted Stock Vesting entry for 26,763 shares on 03/11/2026.
PRVA filed a Form 144 to sell 6,453 shares of Common Stock. The filing lists the proposed sale as resulting from restricted stock vesting tied to compensation with a transaction date of 03/11/2026 and names Fidelity Brokerage Services LLC as the broker. The filing also lists multiple sales by David Mountcastle during the prior three months: 23,887 shares on 12/12/2025, 5,361 shares on 02/26/2026, 7,697 shares on 02/27/2026, 5,177 shares on 03/06/2026, and 5,829 shares on 03/09/2026, with dollar proceeds listed alongside each sale.
PRVA submitted a Form 144 reporting a proposed sale of 21,097 shares of Common Stock. The filing lists the broker Fidelity Brokerage Services LLC and dates around 03/08/2026–03/10/2026.
The filing also discloses recent sales by Parth Mehrotra: 21,440 shares on 03/06/2026 for $496,357.44 and 41,999 shares on 03/09/2026 for $960,197.55.
Privia Health Group CEO Parth Mehrotra reported open-market sales of 63,439 common shares of Privia Health Group, Inc. on March 6 and 9, 2026 at weighted-average prices including 22.84, 23.15 and 23.37 per share. The filing explains these were nondiscretionary “sell-to-cover” trades required to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units and were executed under a Rule 10b5-1 trading plan. After these transactions, Mehrotra directly holds 343,795 shares of Privia common stock.